Company / Working Capital
Adaptimmune Therapeutics PLC Working Capital History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$123.6M
FY2024
5-year range
$123.6M / $359.1M
FY2020-FY2024
Trend
-8.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $359M in FY2020 to $124M in FY2024.
Based on SEC 10-K filings.
$124M in FY2024 with a 5-year CAGR of +7.5%.
Declined from $191M to $124M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -29.5%
- 5-Year CAGR
- +7.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's working capital has declined for 4 consecutive years.
- 5-year CAGR of +7.5%, indicating consistent growth.
- In FY2024, working capital decreased 8.3% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $123.6M | -8.3% |
| FY2023 | $134.8M | -29.4% |
| FY2022 | $190.9M | -45.9% |
| FY2021 | $352.9M | -1.7% |
| FY2020 | $359.1M | +316.8% |
| FY2019 | $86.1M | -58.3% |
| FY2018 | $206.7M | +32.6% |
| FY2017 | $155.9M | -1.6% |
| FY2016 | $158.5M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026